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Abstract
This study aimed to evaluate the efficacy of imi-
dacloprid 10 %/moxidectin 2.5 % (w/v) spot-on 
(Advocate®/Advantage® Multi, Bayer) against 
adult Dirofilaria repens in a blinded, placebo-
controlled randomised laboratory study. Twenty-
four Beagle dogs were experimentally infected 
with approximately 75 infective D. repens larvae 
each on study day (SD) 0. Treatment was initiated 
on SD 228 after patency had been confirmed in 
21 dogs, using a modified Knott Test. Eleven 
dogs received monthly treatments with imida-
cloprid/moxidectin at the minimum therapeutic 
dose (10 mg/kg imidacloprid and 2.5 mg/kg moxi-
dectin) for six consecutive months and 12 control 
dogs were treated with a placebo formulation. 
Approximately one month after the last treat-
ment, all dogs were euthanised and necropsied 
for the detection of  D. repens worms. Eleven con-
trol dogs harboured live adult D. repens (range 
2–11, geometric mean 5.44). Eight of 11 imida-
cloprid/moxidectin-treated dogs were free of 
live worms. The live worm count was reduced 
by 96.2 % (range 0–1, geometric mean 0.21). The 
majority of dead worms were encapsulated and 
degenerated. After the first treatment, Knott 
Tests were negative in all imidacloprid/moxidec-
tin-treated dogs and this status was maintained 
in 10 dogs until study end. One dog showed a 
low microfilariae count (1 and 4/mL) on four 
occasions but was also negative before necropsy. 
The treatment was well tolerated by all study 
animals. It is concluded that six consecutive 
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monthly treatments with imidacloprid/moxidec-
tin spot-on are effective and safe against adult 
D. repens and provide an option for preventing 
the further spread of this zoonotic parasite.
Introduction
In recent years human dirofilariosis has been 
considered an emerging zoonosis in Europe 
(Genchi et al. 2011). The majority of human 
cases are attributed to Dirofilaria repens, a 
mosquito transmitted filarial nematode, which 
causes subcutaneous dirofilariosis in dogs, cats 
and wild canids (Simón et al. 2012). It has been 
shown not only that infection rates are increas-
ing in well-known endemic areas in southern 
Europe, but also that the disease is spreading 
towards northern and eastern areas formerly 
free of the infection (Genchi et al. 2011, Tasić-
Otašević et al. 2015). Recently, Tappe et al. 
(2014) described the first autochthonous human 
case in Germany, after a series of cases in dogs 
in previous years had indicated the occurrence of 
D. repens there (Hermosilla et al. 2006, Pantchev 
et al. 2009, Sassnau et al. 2009). Since the para-
site has also been repeatedly detected in a local 
mosquito population in Germany, a stable local 
transmission is now assumed (Czajka et al. 2014; 
Kronefeld et al. 2014). 
Adult D. repens live and mate mainly in the sub-
cutaneous tissue and perimuscular fasciae and 
female worms release their offspring, the micro-
filariae (MF), into the blood stream. After being 
taken up by a blood feeding mosquito, these 
microfilariae develop into infective third stage 
larvae (L3) and are then transmitted to the next 
host during a subsequent blood meal (Webber 
and Hawking 1955). Dogs represent the main 
reservoir, and thus the only effective way to pro-
tect humans from the disease is to control the 
infection in dogs (Genchi et al. 2010). Difficulties 
in putting this into practice arise from the fact 
that infected dogs are often asymptomatic and 
hence remain undiagnosed, or symptoms that 
may occur, such as pruritus, dermal swelling, 
hyperpigmentation or subcutaneous nodules are 
misinterpreted. In addition, options to treat dogs 
against D. repens are limited since no adulticidal 
drug is available.
Macrocyclic lactones, which are labelled to 
prevent heartworm disease and are used in 
higher doses to clear dogs of the microfilariae 
of Dirofilaria immitis, showed variable results 
against D. repens. In field studies, ivermectin at 
the recommended dose for heartworm preven-
tion effectively prevented patent infections with 
D. repens when administered within 30 days 
after the start of the transmission season (Mar-
concini et al. 1993; Pollono et al. 1998). In some 
European countries ivermectin is registered for 
this indication. However, in studies with dogs 
experimentally infected four times at intervals 
of 15 days and treated 30 and 60 days after the 
first infection, efficacy of ivermectin was incom-
plete. Four times the recommended dose for 
heartworm prevention reduced worm burdens 
by 87.9 % (Cancrini et al. 1989). For treatment 
against microfilariae monthly doses of 6 µg/kg 
ivermectin were not as effective against D. repens 
as they were against D. immitis (Venco et al. 
2004). Sassnau et al. (2009) successfully treated 
microfilaraemic dogs with weekly administra-
tions of 50 µg/kg ivermectin in combination with 
daily doxycycline for a period of 6 weeks. Similar 
results were obtained by Gianelli et al. (2013) 
with doxycycline for 30 days and low dose iver-
mectin (6 µg/kg) twice a month for 6 months. 
Treatment with doxycycline has been shown to 
weaken or even kill filarial nematodes by killing 
their endosymbionts (Wolbachia). Although it is 
not yet clear whether there is true synergism 
or just an additive effect, the combination of 
doxycycline/ivermectin has a much higher effi-
cacy than ivermectin alone against D. immitis 
(Kramer and Genchi 2014).
The efficacy of selamectin at the recommended 
dose for heartworm prevention has been de- 
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monstrated in a field study (Genchi et al. 2002). 
While 41 % of control dogs became infected, all 
treated dogs were negative following the trans-
mission season. The microfilaricidal effect has 
been evaluated by Jacsó et al. (2010) treating 
naturally infected dogs monthly or twice a 
month for a period of 6 or 9 months. Overall, 65 % 
of the dogs were cleared of microfilariae. A single 
case describes the elimination of microfilariae 
by application of 0.4 mg/kg doramectin 5 days 
after treatment with melarsomine (Baneth et al. 
2002). 
The ability of oral milbemycin oxime to prevent 
infections with D. repens was tested in one field 
study. None of the dogs treated monthly with 
the recommended dose became microfilaraemic, 
while 6 of 114 control dogs became infected. All 
positive dogs were successfully treated with 
milbemycin oxime, but the exact treatment pro-
tocol was not described (Di Cesare et al. 2014).
Oral and injectable formulations of moxidectin 
have shown preventive efficacy against D. repens 
in field studies (Rossi et al. 2002, 2004), and 
the efficacy of an injectable sustained-release 
formulation was confirmed in experimentally 
infected dogs (Genchi et al. 2010). In some Euro-
pean countries the formulation is licensed for 
the prevention of skin lesions and dermatitis 
caused by D. repens. The preventive efficacy of 
moxidectin in a spot-on formulation of imidaclo-
prid/moxidectin (Advocate®/Advantage® multi, 
Bayer) has been demonstrated in a field trial 
(Traversa et al. 2013) and was confirmed in a 
laboratory study with dogs receiving a challenge 
infection 4 weeks after a single treatment at the 
minimum therapeutic dose. No worms were 
detected at necropsy in any of the treated dogs 
(Genchi et al. 2013). The potential of the spot-
on formulation to eliminate microfilariae has 
been investigated by various authors. In a study 
by Traversa et al. (2011) a single application 
cleared microfilariae in all 18 treated dogs. 
16 dogs stayed negative throughout the obser-
vation period of 5 to 6 months after treatment. 
Two dogs had recurring microfilaraemia 2 and 
3 months after treatment respectively. In another 
field study all 18 treated dogs became a micro-
filaraemic after the first treatment and stayed 
negative throughout an observation period of 3 to 
4 months after treatment (Hellmann et al. 2011). 
Fok et al. (2010) evaluated different treatment 
protocols comprising multiple applications, i.e., 
once a month for 3 or 6 months or every 2 weeks 
for 6 months. Thirty-eight out of 44 treated dogs 
were free of microfilariae 2 weeks after the initial 
treatment, and after one month only one dog still 
showed a low microfilaraemia. After the second 
treatment, all dogs were negative and no recur-
rence of microfilaraemia was detected through-
out an observation period of 6 months after the 
last treatment. Similar results were obtained by 
Paran et al. (2011) with 4 consecutive monthly 
treatments. All 11 dogs were negative for micro-
filariae of D. repens after the first treatment 
and, again, this status persisted for 6 months 
after the last treatment. In the European Union 
imidacloprid/moxidectin spot-on is registered for 
the prevention of skin dirofilariosis and for the 
reduction of D. repens microfilariae. 
Currently no marketed product with an adultici-
dal claim against D. repens exists. Surgical 
removal of adult worms may be performed when 
the worms are located in nodules under the skin 
but not when they reside in deep tissues or even 
in visceral cavities. In addition, it can be difficult 
to locate the worms under the skin as they tend 
to alter their position. The only licensed active 
against adult heartworms is melarsomine, an 
arsenic drug which needs multiple intramuscu-
lar administrations for adequate efficacy. While 
some case reports describe the use of melarso-
mine against skinworms (Baneth 2002), the 
efficacy of the drug against D. repens has not 
been confirmed in clinical studies (Genchi, per-
sonal communication).
Studies that evaluated the microfilaricidal 
pro perties of imidacloprid/moxidectin spot-on 
showed long-term suppression of microfilaraemia, 
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suggesting that the treatment might also have a 
killing effect on adult stages of D. repens (Fok 
et al. 2010). The present study was therefore 
designed to test this hypothesis under controlled 
laboratory conditions.
Materials and methods
The study was performed as a monocentric, pla-
cebo-controlled, randomised and blinded efficacy 
study. Investigations were conducted in accord-
ance with VICH Guideline 9 “Good Clinical Prac-
tice” (July 2001) and the recommendations given 
in VICH Guideline 7 “Efficacy of anthelmintics: 
general requirements” (December 2000), VICH 
Guideline 19 “Efficacy of anthelmintics: Specific 
Recommendations for Canine” (July 2002) and the 
WAAVP guidelines for evaluating the efficacy of 
anthelmintics for dogs and cats (Jacobs et al. 1994) 
were followed. Since these guidelines do not include 
any specific recommendations for D. repens, the 
infection protocol was based on scientific know-
ledge and experience from previous experimental 
studies. The reliability of the infection protocol 
had been confirmed in studies on the prevention 
of experimental D. repens infection in dogs (Genchi 
et al. 2010, Genchi et al.  2013).
Study animals
Twenty-four purpose-bred Beagle dogs (12 male/ 
12 female) were included in the study. At study 
start the dogs were 10 months old and weighed 
between 7 and 12.2 kg. Twenty-three dogs were 
finally evaluated. They had been vaccinated 
according to their age against all major canine 
infectious diseases. Revaccination was not con-
ducted during the study to avoid interference 
with the treatment. Treatment with drugs that 
could influence the study results, especially 
macro cyclic lactones, was not allowed for a period 
of at least three months before study start. All 
dogs were acclimatised for at least nine days 
before infection. They were housed in indoor 
kennels in social groups of three to six animals 
of the same sex. After the first treatment, dogs of 
the same treatment group were housed together 
except for a period of two days after each treat-
ment when all dogs were housed singly to avoid 
cross-contamination between dogs. The dogs 
were fed a standard commercial dog food and 
water was available ad libitum. They received 
toys and chewing material for environmental 
enrichment, had daily access to an outdoor exer-
cise area and human interaction periods at least 
once a day. Before onset of patency, protective 
measures (nylon fabric) were taken to avoid the 
migration of mosquitoes into the animal main-
tenance area. Husbandry complied with the 
“Commission recommendation on guidelines for 
the accommodation and care of animals used 
for experimental and other scientific purposes” 
(European Commission, 2007/526/EC, 18 June 
2007).
Health observations
General health observations were conducted daily 
and the dogs were physically examined at the start 
of the acclimatisation period, before infection and 
prior to the first treatment. Only healthy dogs were 
included in the study. On treatment days, clinical 
assessments were performed before treatment and 
approximately 1, 4 and 24 hours after treatment 
for the detection of adverse effects. Body weights 
were determined on all treatment days for dose 
calculation and at least every 4 weeks throughout 
the study period.
Experimental infections
On study day (SD) 0 each dog was injected subcuta-
neously with approximately 75 infective D. repens 
larvae (L3). Preparation of infection material was 
performed as previously described (Genchi et al. 
2010). In brief, 4-day-old Aedes aegypti mosqui-
toes were fed on blood collected from a naturally 
D. repens-infected dog in Italy. The heparinised 
blood was maintained at 37 °C in a feeding appa-
ratus and the mosquitoes were allowed to feed for 
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60 minutes. After 28 days, shortly before the experi-
mental infection, infective third stage larvae were 
collected and maintained in RPMI-medium. For 
each infection dose approximately 75 larvae were 
manually collected using a glass pipette and trans-
ferred to tubes containing 1.5 mL RPMI-medium. 
Allocation and treatment
On SD 227, the dogs were randomly allocated to 
two study groups based on sex and their highest 
microfilariae count of 4 Knott tests performed 
between SD 164 and 220. After randomisation each 
group consisted of 12 dogs with equal sex distribu-
tion. Dogs in the treatment group were dosed with 
the recommended minimum therapeutic dose of 
imidacloprid (10 mg/kg) and moxidectin (2.5 mg/
kg), corresponding to 0.1 mL spot-on formulation 
per kg body weight. In the control group a placebo 
spot-on formulation was used at the same amount 
of 0.1 mL spot-on formulation per kg body weight 
to mimic the appearance of the moxidectin/imida-
cloprid spot-on. Six consecutive treatments were 
performed at 4-weeks intervals (SD 228, 256, 284, 
312, 340 and 368).
Three dogs, that were still microfilariae-negative 
on SD 227, were also included in the treatment 
phase and randomly allocated to the study groups. 
However, irrespective of the study group the dogs 
were allocated to, all microfilariae-negative dogs 
were treated with placebo, i.e. there were two nega-
tive dogs in the placebo group and one in the imida-
cloprid/moxidectin group.
Blood sampling
A modified Knott test was used for the detection 
of circulating MF of D. repens. Blood samples 
were taken from all 24 dogs in the late afternoon 
(4:00 p.m. to 6:00 p.m). For study inclusion the dogs 
had to be negative for D. repens. The onset of patency 
was monitored on SD 164, 178, 192 and 220 post 
infection. After the first treatment, the course of 
microfilaraemia was followed monthly until study 
end (SD 256, 283, 311, 339, 367 and 395). Micro-
filaraemia was quantified by screening the whole 
sediment or, if the density was high, by counting a 
representative sample. Species confirmation was 
done by PCR (Polymerase Chain Reaction) analysis. 
Three primer pairs were used: pan-filaria primers 
(Rishniw et al. 2006) that detect different Dirofi-
laria species (D. repens, D. immitis, D. reconditum), 
different Brugia species (B. pahangi, B. malayi, 
B. timori) as well as Acanthocheilonema dracuncu-
loides and Onchocerca volvulus, and primer pairs 
specific for D. repens and D. immitis (Favia et al. 
2000; Hermosilla et al. 2006). In the case of a weak 
positive PCR result with pan-filaria primers and 
a negative result with D. repens species-specific 
primers, a sequence analysis was performed to 
verify the species. 
Necropsy
Thirty-five to 36 days after the last treatment (SD 
403/404), the dogs were euthanised and subsequently 
necropsied. The dogs were completely skinned and 
the subcutaneous tissue and fat, muscular fasciae 
and scrotum were carefully visually inspected for the 
presence of adult and pre-adult D. repens worms and 
any nodules suspected of containing worms or worm 
fragments. Thereafter, the abdominal and thoracic 
cavities were opened and also examined for worms. 
Skin and carcasses were then immersed in warm 
water (approximately 38 °C) for 20 minutes. After 
that, the skin was re-examined for the presence of 
parasites. The water from the basins was passed 
through sieves and the retained material was also 
examined for the presence of D. repens. Worms were 
collected in Petri dishes containing warm isotonic 
saline solution, identified for developmental stage 
and sex and counted. The mobility of the worms 
was checked in order to distinguish between live 
(mobile) and dead (immobile) worms. In addition, 
the worms and nodules were investigated under a 
stereomicroscope for any other characteristics and 
specific findings such as signs of degeneration.
Efficacy determination and statistical analysis
The adequacy of infection was determined accord-
ing to VICH Guidelines 7 and 19. These require a 
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minimum of 6 animals in the control group with at 
least 5 worms each. 
The efficacy was based on live worm counts in the 
study groups and calculated according to VICH 
Guideline 7 and the WAAVP guideline for evalu-
ating the efficacy of anthelmintics for dogs and cats 
(Jacobs et al. 1994) as follows:
% Effectiveness (reduction) = (N1–N2)/N1 x 100
N1:  geometric mean (GM) of live D. repens counts in the 
control group
N2:  geometric mean (GM) of live D. repens counts in the 
treated group
Due to the presence of worm count values of “0”, 
all counts were modified by adding 1 prior to log 
transformation and subtracting 1 from the antilog 
value. The non-parametric Wilcoxon rank sum test 
(two-tailed, α = 0.05) was used to test for a treat-
ment group (imidacloprid/moxidectin vs. placebo) 
effect. Live, dead and the total worm counts as well 
as microfilariae counts on all testing dates were 
evaluated. The analyses were performed using 
SAS software 8.2 (SAS Institute, Cary, North 
Carolina, USA, 2001).
Results
Knott Test and PCR
On SD 164 eleven of 24 dogs were microfilarae-
mic. This number increased to 21 positive dogs on 
SD 220 and treatment was therefore initiated on 
SD 228. Two negative dogs were allocated to the 
control group. The Knott Test in these two dogs 
was positive on SD 256, and at necropsy they were 
shown to be adequately infected. Consequently, 
these dogs were included in the efficacy calcu-
lations. The third negative dog was allocated to 
the treatment group to give an equal number of 
dogs in the study groups. However, this dog was 
treated with the placebo solution and was therefore 
excluded from the efficacy calculation. PCR analy-
sis of the 21 positive samples on SD 220 identified 
D. repens DNA in 19 samples. In two samples with 
a weak positive PCR result with the pan-filaria 
primers and a negative result with the D. repens 
species specific primers, the species was confirmed 
by sequence analysis. In two samples (dog nos. 
101 and 121) microfilaraemia on SD 220 was too 
low to detect DNA.
After randomization there were no statistically 
signi ficant differences in the geometric mean 
values of the pre-treatment microfilariae counts 
between the study groups. Four weeks after the 
first treatment, all dogs treated with imidacloprid/ 
moxidectin spot-on were amicrofilaraemic and 
this status was maintained until study end, except 
for one dog that showed low microfilariae counts 
(i.e. 4 and 1 MF/mL) between SD 283 and 367. In 
the control group microfilariae counts were posi-
tive in 9 of 12 dogs from SD 256 to 339. Two dogs 
with low microfilaraemia (ID 105 and 109) were 
negative on the last two evaluation dates. One 
dog (ID 121) with a positive Knott Test between 
SD 178 and 220 was negative for the rest of the 
evaluation period. On all post-treatment evalu-
ation dates there was a statistically significant 
difference between the treated and the control 
group (Table 1).
Efficacy evaluation
Due to exclusion of one dog, 12 dogs were evalu-
ated in the control group and 11 in the treatment 
group. Nine of 12 control dogs harboured 5 or more 
live worms at necropsy (Fig. 1). Hence, the require-
ments for the adequacy of infection with D. repens 
were fulfilled. With the exception of one dog (ID 
105), live D. repens were isolated from all control 
animals (range 2–11). Eight of 11 dogs treated with 
imidacloprid/moxidectin spot-on were free of live 
worms at necropsy. In the remaining three, one live 
female D. repens was found in each dog. Based on 
geometric means of live worm counts, the efficacy 
was 96.2 % (p < 0.0001).
The number of dead worms ranged between 0 and 
4 (geometric mean 1.41) in the control group and 
between 2 and 16 (geometric mean 5.94) in the 
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Table 1 Pre and post treatment individual microfilariae counts in the study groups







101 0 2 6 2 0 0 0 0 0 0
102 16 122 370 340 0 0 0 0 0 0
103 4 33 660 2810 0 0 0 0 0 0
106 0 0 4 35 0 0 0 0 0 0
110 2 30 30 32 0 0 0 0 0 0
112 2 16 45 83 0 0 0 0 0 0
115 0 23 500 440 0 0 0 0 0 0
117 0 89 910 4170 0 0 0 0 0 0
119 0 0 310 420 0 0 0 0 0 0
122 107 510 3710 6100 0 0 0 0 0 0
123 5 99 810 1320 0 4 1 1 1 0





104 2 6 25 62 229 1540 1080 610 1400 140
105 0 0 7 10 3 3 7 1 0 0
107 0 11 66 123 43 544 1150 250 740 770
108 9 117 630 2420 2370 4930 4800 1000 2800 1500
109 0 0 0 0 4 54 40 1 0 0
113 6 31 2630 2700 271 6040 2100 2050 3100 5200
114 0 4 3 76 18 507 960 520 60 580
116 9 195 800 910 55 740 570 600 110 65
118 0 23 310 1100 279 3450 2100 700 560 490
120 2 126 1620 3020 145 9050 9600 2100 1500 270
121 0 34 350 2 0 0 0 0 0 0
124 0 0 0 0 6 71 354 1540 450 5880
Geometric mean 1.07 12.39 68.69 91.52 41.98 358.50 397.78 175.19 128.95 129.97
p-value 0.5468 0.6600 0.4219 0.3551 < 0.0001 < 0.0001 < 0.0001 < 0.0001 0.0006 0.0003
treated group. There was a statistically significant 
difference between the study groups, with the treat-
ed dogs harbouring significantly more dead worms 
(p = 0.0013). The majority of dead worms were either 
encapsulated, degenerated or both (Fig. 2 and 3). 
Histopathology of subcutaneous  nodules revealed 
signs of inflammation and a capsule/demar cation 
containing structures which were likely of parasitic 
origin or identified as worms. To some extent mine-
ralisation was present (Fig. 4 and 5). The total 
number of worms (live + dead) ranged between 
2 and 14 (geometric mean 7.72) in the control group 
and between 2 and 16 (geometric mean 6.25) in 
the treated group. There was no statistically 
significant difference in the total worm counts 
between the study groups (p = 0.5127) (Table 2).
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Fig. 2 Dead adult D. repens in capsule on the perimus-
cular fascia following skin removal. Right half of the 
capsule was cut open.
Fig. 3 Remnant of dead adult D. repens on the perimus-
cular fascia following skin removal
Fig. 1 Live adult D. repens in the abdominal cavity on 
the serosa
Fig. 5 HE colored micrograph of a dead D. repens in a 
capsule (Enlargement of Fig. 5). Arrowheads show the 
slightly inflamed fibrous capsule. Arrows show degen-
erating inner structures of the worm with beginning 
mineralization (scale bar 50 µm)
Fig. 4 HE colored micrograph of a dead adult D. repens 
in a capsule. Arrowheads show the thin slightly inflamed 
fibrous capsule build around the worm by the dog.  
Arrows show cuts of the worm. Frame shows area of   
Fig. 5 (scale bar 500 µm)
The majority of worms were found in the subcu-
taneous tissue. Five control animals harboured a 
total of 8 live and 1 dead worm in visceral cavities. 
Six worms were found in the abdominal cavity and 
3 in the thoracic cavity. One dead worm was found 
in the abdominal cavity of a treated dog.
Health observations
Treatment with imidacloprid/moxidectin spot-on 
was well tolerated in all dogs. No clinical signs of 
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intolerance were observed. The whole study popu-
lation stayed clinically healthy throughout the 
study period. Minor findings like scratch or bite 
wounds, salivation and vomiting were observed in 
individual animals on single occasions. Soft to firm 
nodules or partly thickened skin on at least one 
occasion were observed in 5 treated dogs and in 
2 control animals. The first observations of these 
signs were made on SD 164. After treatment the 
incidence of these findings increased slightly in the 
imidacloprid/moxidectin treated group. At study 
end these signs were present in one control animal 
but in none of the treated dogs.
Discussion
This study demonstrated the adulticidal efficacy 
of six consecutive monthly treatments with imida-
cloprid/moxidectin spot-on (Advocate®/Advantage 
multi®, Bayer) against D. repens in experimentally 
infected dogs. The adequate infection of the control 
Table 2 Individual D. repens counts at necropsy
Dog 
ID
Live D. repens Dead D. repens Live + dead











101 0 0 0 0
0.21/
96.2 %




102 0 0 0 0 6a 7a 0 13 13
103 0 1 0 1 0 0 3c 3 4
106 0 0 0 0 0 2a 0 2 2
110 0 0 0 0 0 0 1a/8c 9 9
112 0 0 0 0 0 0 1/2a/1c 4 4
115 0 0 0 0 0 0 1a/3c 4 4
117 0 0 0 0 0 0 1a/1c 2 2
119 0 1 0 1 0 0 3a/2c 5 6
122 0 1 0 1 0 0 1/3a/1b/4c 9 10
123 0 0 0 0 0 0 2/9a/1b/1c 13 13
Placebo
104 4 6 0 10
5.44




105 0 0 0 0 0 2a 0 2 2
107 3 3 0 6 0 0 3c 3 9
108 2 9 0 11 0 0 0 0 11
109 3 5 2 10 0 0 1/3c 4 14
113 2 4 0 6 0 0 0 0 6
114 1 1 0 2 0 0 3c 3 5
116 2 3 0 5 0 4a 0 4 9
118 2 1 1 4 0 0 1c 1 5
120 0 10 0 10 0 0 0 0 10
121 3 5 0 8 0 1a 2a 3 11
124 2 5 0 7 0 0 1c 1 8
n.d. = sex not determinable;  a encapsulated;  b degenerated;  c encapsulated+degenerated
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group proved the reliability of the infection model 
and the infection rate was within ranges formerly 
experienced with this infection dose (Genchi et al. 
2010; Genchi et al. 2013.) The onset of patency was 
earlier than expected. According to the literature 
the prepatent period of D. repens is 27–34 weeks 
(Manfredi et al. 2007). Webber and Hawking 
(1955) identified the first positive blood samples at 
25 weeks post infection. In the actual study, how-
ever, 11 dogs were already positive at 23 weeks post 
infection.
Due to missing data in the literature it was not 
clear what picture could be expected at necropsy 
and how adult D. repens killed by an anthelmin-
tic would present. It became obvious that most 
dead worms were encapsulated or degenerated 
or both, but still clearly identifiable at necropsy. 
The achieved efficacy of 96.2 % was therefore 
based on the “live worm count”. The total num-
ber of worms (live + dead) did not significantly 
differ between the study groups, indicating a 
similar degree of initial infection in both groups 
before treatment was started. The monthly 
treatment was well tolerated by all dogs. The 
higher incidence of soft to firm nodules in/under 
the skin in the imidacloprid/moxidectin group 
can be explained by the fact that dying worms 
apparently tend to coil up (Fig. 2 and 3) and that 
these “worm clusters” are then demarcated as a 
response from the surrounding tissue and form 
typical granulomatous inflammations (Fig 4 and 
5). Although these structures could be identified 
at necropsy, the nodules had obviously become 
too soft and too small to be detected during the 
clinical veterinary examination directly before 
necropsy of the treated group.
In previous studies that evaluated the microfilari-
cidal efficacy of an imidacloprid/moxidectin spot-
on against D. repens, it was supposed that multiple 
applications might also have an adulticidal effect 
(Fok et al. 2010). However, these assumptions 
were made on the basis of the sustained absence 
of microfilariae and/or disappearance of clinical 
symptoms. To the best of our knowledge, this is the 
first study to demonstrate the adulticidal efficacy 
of an anthelmintic against D. repens by ne cropsy. 
This study was necessary, as no other test is avail-
able to detect the presence or absence of adult 
skinworms, and testing for microfilariae does not 
provide reliable data due to the fact that infections 
with premature worms or unisex infections cannot 
be detected. Finally, clearance of microfilariae is 
not a measure of adulticidal efficacy. As has been 
shown for D. immitis, microfilariae may reappear 
even a long time after treatment with macrocyclic 
lactones has been withdrawn (reviewed by Bow-
man and Mannella 2011). In fact, this observa-
tion was also made in a study that evaluated the 
efficacy of a single administration of imidacloprid/
moxidectin spot-on in eliminating D. repens micro-
filariae. After all dogs had been tested negative, 
two dogs were microfilaraemic again two and three 
months after treatment (Traversa et al. 2011).
The adulticidal efficacy of macrocyclic lactones, 
especially ivermectin, against filarial nematodes 
has been extensively studied in heartworm disease 
(see McCall 2005 for a summary). While larval stag-
es (L3/L4) are effectively killed, long-term adminis-
tration is necessary for premature and adult worms, 
and the older the worms are when first exposed to 
macrocyclic lactones, the longer it takes them to die. 
Three-months-old  larvae require up to one year and 
mature adults 2.5 years of monthly application of 
preventive doses of ivermectin (6 µg/kg) to provide 
efficacy of at least 95 % (McCall et al. 2008). Also, 
higher doses of ivermectin (200 µg/kg) and shorter 
treatment intervals did not greatly enhance the 
efficacy (McCall 2005). This so-called “slow-kill” 
method is not re commended in heartworm disease 
as the infection persists throughout this long period 
and pathology progresses. Additionally there are 
concerns that the stand-alone therapy with iver-
mectin has the potential for selection of resistant 
subpopulations of heartworms (AHS 2014). 
The effect of imidacloprid/moxidectin spot-on 
against adult heartworms has not been tested in 
the context of an efficacy study. But as the prod-
uct is registered for the treatment of D. immitis 
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microfilariae, the aspect of adulticidal efficacy 
has been addressed by conducting overdose target 
animal safety studies in dogs with existing heart-
worm infections. Laboratory studies with doses up 
to 5 times the recommended dose (up to 13.6 times 
the minimum therapeutic dose) given 3 times at 
2-week intervals showed no significant differences 
in the numbers of adult heartworms collected at 
necropsy compared to a placebo-treated control 
group (EMA 2009). 
In contrast to D. immitis, the study presented 
here demonstrated a high efficacy of imidacloprid/
moxi dectin topical solution against adult D. repens. 
Besides possible differences in susceptibility to 
moxidectin between the two species, this can prob-
ably be explained by two facts that are directly 
related: the location of the adult worms and the 
pharmacokinetic profile of moxidectin. While adult 
D. immitis float in the blood stream of the right 
heart and pulmonary artery, D. repens migrates 
mainly in the subcutaneous tissue. Moxidectin is 
widely distributed into tissues and, due to its high 
lipophilicity, is mainly deposited in fat (Vanapalli 
et al. 2002). Adipose tissue may therefore act as 
a drug reservoir that contributes to the long per-
sistence of moxidectin in the body. Compared to 
ivermectin and doramectin, it has the longest 
elimination half-life (19 days in the dog) (Vanapalli 
et al. 2002). Dirofilaria repens, dwelling in tissue 
rich in fat, is thus subjected to long-term exposure 
to high doses of moxidectin, which could account 
for the strong killing effect demonstrated in this 
study. In addition, it has been demonstrated that 
continuous monthly application of the formula-
tion will lead to constant high levels of the drug in 
serum and tissue, which explains the far-reaching 
capabilities of the formulation to control in particu-
lar tissue dwelling parasites such as skin-burrow-
ing Demodex mites (Paterson et al. 2014) and lung 
nematodes (Conboy et al. 2009).
In contrast to classical heartworm preventives, 
imidacloprid/moxidectin spot-on has demonstrated 
high efficacy against microfilariae in this study and 
in several other studies before. In many cases dogs 
were cleared of microfilariae with a single applica-
tion. The topical solution was originally developed 
as a broad-spectrum anthelmintic against gastro in-
testinal nematodes. Compared to third and fourth 
stage larvae of D. immitis and D. repens, these endo- 
parasites require much higher doses of macro cyclic 
lactones to be effectively killed. Consequently the 
recommended minimum dose is many times higher 
than the 3 µg/kg moxidectin or 6 µg/kg ivermectin 
provided by classical heartworm pre ventives. 
It can be concluded, that treatment with imidaclo-
prid/moxidectin spot-on for six consecutive months 
is safe and efficacious against adult D. repens in 
dogs. Together with the new findings from this 
study the spot-on now provides a complete option 
for the control of subcutaneous dirofilariosis, 
including prevention, elimination of microfilariae 
and treatment of adult stages. Spot-on treatment 
is a convenient application method and thus the 
formulation has the potential to enhance owners’ 
compliance in protecting their dogs in endemic 
areas and treating D. repens-positive dogs, even in 
cases where the infection is asymptomatic. Elimi-
nating the parasite from the reservoir is of capital 
importance to prevent the further spread of the 
disease and to protect animals as well as human 
beings from becoming infected.
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